Lung cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• EGFR 301
• PD-L1 162
• PD-1 156
• KRAS 97
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• VEGF 23
• mTOR 0
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• TROP2 14
• CTNNB1 0
• RAS 15
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK6

  ISRM Research Career Scientist Award Application

  Veterans Health Administration· Pittsburgh, United States· until Sept 2031

• NIH NIEHS · F31

  PhosFate: Investigating Chemical Hazards, Community Exposures, and Health Risks from Phosphate Fertilizer Manufacturing

  University of South Florida· Tampa, United States· US$41,102 awarded in fiscal year 2026· until Sept 2028

• NIH NIDCR · F32

  Transposon derived neo-antigens in NSD1 mutant Head and Neck Cancers

  Columbia University Health Sciences· New York, United States· US$77,580 awarded in fiscal year 2026· until Sept 2028

• NIH NCI · R01

  Role of Allostatic Load in Immunotherapy Outcomes

  Ut Southwestern Medical Center· Dallas, United States· US$389,844 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R21

  Tackling tumor recurrence in pediatric brain tumors: identification of epigenetic memory and tumor microenvironment conducive to tumor recurrence in an inducible and reversible H3K27M murine model.

  University of Michigan at Ann Arbor· Ann Arbor, United States· US$401,115 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Designing Programmable MOF-nanocomposites for Synergistic, Redox-Driven Antitumor Therapies (Photo-bioMOF)

  Fundacion IMDEA Energia· Mostoles Madrid, Spain· EU contribution €262,393· until Feb 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Identifying and disrupting neuroimmune circuits in cancer (NeuroCAN)

  Universitat Basel· Basel, Switzerland· EU contribution €1,874,590· until Jun 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, France· EU contribution €242,261· until Mar 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Dual Amplification Photoelectrochemical Platform for KRAS Mutation Detection (PEAKRAS)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution €216,240· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  KRAS Targeting in Oncogenic Systems: reconstructing the KRAS signalling network to identify optimal drug combinations (KRATOS)

  University College Dublin, National University of Ireland, Dublin· Dublin, Ireland· EU contribution €426,534· until Jan 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 1,451 running projects, newest first. Listed amounts together: US$841.1m + €224.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

  NCT06130254· M.D. Anderson Cancer Center· Updated 9 Apr 2026

  “Sponsor discontinued the trial”Registry text, quoted unchanged. Source

• Withdrawn

  Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT04267913· SWOG Cancer Research Network· Updated 20 Nov 2020

  “The pharmaceutical company sold the compound and pulled out.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

  NCT06008093· AstraZeneca· Source

• NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

  NCT06494540· AstraZeneca· Source

• DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

  NCT07249372· NYU Langone Health· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 314
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 67
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 191
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 618
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 116
• Machine Learning 290
• Deep Learning 211
• Cohort Studies 289
• Genome-Wide Association Study 75

• RNA-Adjusted TUFM Protein State Captures Mitochondrial Proteome Organization in Lung Adenocarcinoma.

  J Proteome Res, Nov 2026

• Midkine drives lung cancer brain metastasis via the NOTCH2/HES1 and PI3K/AKT pathways and serves as a prognostic biomarker.

  Cancer Biomark, Nov 2026

• Spatial proteomics profiling reveals oncogene-specific immune niches and prognostic markers in non-small cell lung cancer.

  Am J Respir Crit Care Med, Nov 2026

• Distinct Molecular Pathways Driving Thymic and Pulmonary Neuroendocrine Neoplasms: Organ of Origin Defines Molecular Identity and Yields CD44 as a Marker of Pulmonary Neuroendocrine Tumors.

  Endocr Pathol, Oct 2026

• Olink Platform-Based Identification of Peripheral Blood Biomarkers for irAEs in Advanced NSCLC.

  Curr Oncol, Oct 2026

• Integrated multi-omics, network pharmacology, and machine learning reveal the active constituents and pharmacological mechanism of Fufang E'jiao Jiang against lung cancer-related fatigue.

  Anal Chim Acta, Oct 2026

• A Robust DIA-Based Platform for Large-Scale Plasma Glycoproteomics and Biomarker Discovery.

  J Proteome Res, Oct 2026

• Peroxiredoxin 6 Silencing Remodels Lipid Metabolism and Redox Pathways to Promote Ferroptosis-Mediated Radiosensitization in Nonsmall Cell Lung Cancer.

  J Proteome Res, Oct 2026

• Exploratory analysis of extracellular vesicle Profile changes during pembrolizumab treatment in NSCLC.

  Lung Cancer, Sept 2026

• SpaCEy links spatial tissue patterns to clinical outcomes using explainable graph neural networks.

  Nat Commun, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.